Conclusion:
The main point is that there are several patients with PCP belonging to categories not generally recommended to be treated with prophylactic cotrimoxazole and one of these categories are AML patients. Data in literature are so limited and sparse in association of pneumocystis in patients with AML. It seems that affected patients appear to have a clear resistance to PCP infection despite chemotherapy and bone marrow suppression due to the preservation of a specific immunological milieu in the lung. In fact, may be due to immunological stability of the lungs that remains intact. Further studies can determine the risk of PCP in patients with AML.
Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding : The authors received no financial support for the research, author-ship, and/or publication of this article.